Patient Characteristics Associated with COVID-19 Positivity and Fatality in Nigeria: Retrospective Cohort Study
Overview
Authors
Affiliations
Objective: Despite the increasing disease burden, there is a dearth of context-specific evidence on the risk factors for COVID-19 positivity and subsequent death in Nigeria. Thus, the study objective was to identify context-specific factors associated with testing positive for COVID-19 and fatality in Nigeria.
Design: Retrospective cohort study.
Setting: COVID-19 surveillance and laboratory centres in 36 states and the Federal Capital Territory reporting data to the Nigeria Centre for Disease Control.
Participants: Individuals who were investigated for SARS-CoV-2 using real-time PCR testing during the study period 27 February-8 June 2020.
Methods: COVID-19 positivity and subsequent mortality. Multivariable logistic regression analyses were performed to identify factors independently associated with both outcome variables, and findings are presented as adjusted ORs (aORs) and 95% CIs.
Results: A total of 36 496 patients were tested for COVID-19, with 10 517 confirmed cases. Of 3215 confirmed cases with available clinical outcomes, 295 died. Factors independently associated with COVID-19 positivity were older age (p value for trend<0.0001), male sex (aOR 1.11, 95% CI 1.04 to 1.18) and the following presenting symptoms: cough (aOR 1.23, 95% CI 1.13 to 1.32), fever (aOR 1.45, 95% CI 1.45 to 1.71), loss of smell (aOR 7.78, 95% CI 5.19 to 11.66) and loss of taste (aOR 2.50, 95% CI 1.60 to 3.90). An increased risk of mortality following COVID-19 was observed in those aged ≥51 years, patients in farming occupation (aOR 7.56, 95% CI 1.70 to 33.53) and those presenting with cough (aOR 2.06, 95% CI 1.41 to 3.01), breathing difficulties (aOR 5.68, 95% CI 3.77 to 8.58) and vomiting (aOR 2.54, 95% CI 1.33 to 4.84).
Conclusion: The significant risk factors associated with COVID-19 positivity and subsequent mortality in the Nigerian population are similar to those reported in studies from other countries and should guide clinical decisions for COVID-19 testing and specialist care referrals.
Ahmad S, Aliyu H, Usman R, Abubakar A, Maijawa M, Suleiman B BMJ Open. 2025; 15(1):e083470.
PMID: 39788760 PMC: 11883584. DOI: 10.1136/bmjopen-2023-083470.
Belayneh E, Workneh Leulseged T, Teklu B, Tewodros B, Megiso M, Weldesenbet E Cureus. 2024; 16(8):e67719.
PMID: 39318914 PMC: 11421194. DOI: 10.7759/cureus.67719.
Teka G, Woldeab A, Dereje N, Eshetu F, Gizachew L, Tazu Z PLOS Glob Public Health. 2024; 4(5):e0003175.
PMID: 38781131 PMC: 11115226. DOI: 10.1371/journal.pgph.0003175.
Effect of nasal carriage of species on COVID-19 severity: a cross-sectional study.
Fowora M, Aiyedogbon A, Omolopo I, Tajudeen A, Olanlege A, Abioye A Microbiol Spectr. 2024; 12(2):e0184323.
PMID: 38193730 PMC: 10846055. DOI: 10.1128/spectrum.01843-23.
Taste loss as a distinct symptom of COVID-19: a systematic review and meta-analysis.
Hannum M, Koch R, Ramirez V, Marks S, Toskala A, Herriman R Chem Senses. 2023; 48.
PMID: 38100383 PMC: 11320609. DOI: 10.1093/chemse/bjad043.